Table 6 Targeted drugs and clinical trials related to PD-1

Nivolumab

Nivolumab

Relapsed or refractory HL

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma

1

Completed

87%/17%

NCT01592370

³⁴⁹

Nivolumab

Relapsed or refractory HL

Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicenter, multicohort, single-arm phase 2 trial

2

Completed

66.3%/9%

NCT02181738

³⁵⁰

Nivolumab

Relapsed or refractory NHLs/MM

Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase 1 study

1

Completed

FL, 40%/10%; DLBCL, 36%/18%; T-NHLs, 17%/0%

NCT01592370

³⁸⁶

Nivolumab

Relapsed or refractory DLBCL (failed or not eligible for ASCT)

Study of nivolumab in patients with relapsed or refractory diffuse large B-cell lymphoma that have either failed or are not eligible for autologous stem cell transplant

2

Completed

ASCT-failed, 10.3%/2.9%; ASCT ineligible, 3.4%/0%

NCT02038933

–

Nivolumab

Relapsed or refractory ALK⁺ ALCL

Phase 2 trial of nivolumab for pediatric and adult relapsed or refractory ALK⁺ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (cohort 2)

2

Recruiting

–

NCT03703050

–

Nivolumab

Relapsed or refractory PTCL

Nivolumab in treating patients with relapsed or refractory peripheral T-cell lymphoma

2

Active, not recruiting

–

NCT03075553

–

Nivolumab

Relapsed or refractory PCNSL/primary testicular lymphoma

PD-1 blockade with nivolumab in relapsed or refractory primary central nervous system and testicular lymphoma

2

Completed

100%/80%

NCT02857426

³⁵¹

Nivolumab, BV

Relapsed or refractory HL

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin’s lymphoma

1/2

Completed

82%/61%

NCT02572167

³⁸⁷

Nivolumab, BV

NHLs

An investigational immunotherapy effectiveness and safety study of nivolumab in combination with brentuximab vedotin to treat non-Hodgkin’s lymphomas

1/2

Active, not recruiting

–

NCT02581631

–

Nivolumab, lenalidomide

Relapsed or refractory NHLs/HL

Nivolumab and lenalidomide in treating patients with relapsed or refractory non-Hodgkin’s or Hodgkin’s lymphoma

1/2

Recruiting

–

NCT03015896

–

Nivolumab, rituximab

FL

Nivolumab plus rituximab in first-line follicular lymphoma grade 1-3A

1

Recruiting

–

NCT03245021

–

Nivolumab, cabiralizumab

PTCL

Nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab in patients with relapsed or refractory peripheral T-cell lymphoma

2

Recruiting

–

NCT03927105

–

Nivolumab, rituximab, gemcitabine, oxaliplatin

NHLs (elderly patients)

Nivolumab with gemcitabine, oxaliplatin, rituximab in relapsed or refractory elderly lymphoma patients

2/3

Recruiting

–

NCT03366272

–

Nivolumab, R-CHOP

Aggressive NHLs

Nivolumab and combination chemotherapy in treating participants with diffuse large B-cell lymphoma

1/2

Recruiting

–

NCT03704714

–

Nivolumab, DA-R-EPOCH

Aggressive NHLs

Nivolumab with DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin’s lymphoma

2

Recruiting

–

NCT03749018

–

Pembrolizumab

Pembrolizumab

Relapsed or refractory HL

PD-1 blockade with pembrolizumab in patients with classical Hodgkin’s lymphoma after brentuximab vedotin failure

1

Completed

65%/16%

NCT01953692

³⁵³

Pembrolizumab

Relapsed or refractory HL

Phase 2 study of the efficacy and safety of pembrolizumab for relapsed or refractory classic Hodgkin’s lymphoma

2

Completed

69%/22.4%

NCT02453594

³⁶⁶

Pembrolizumab

Transformed DLBCL/relapsed or refractory CLL

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

2

Completed

transformed DLBCL, 41%/11%; CLL, 0%/0%

NCT02332980

³⁸⁸

Pembrolizumab

Relapsed or refractory PMBCL

Safety and tolerability of pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma

1

Completed

41%/11.8%

NCT01953692

³⁸⁹

Pembrolizumab

Relapsed or refractory GZL/extranodal DLBCL

Pembrolizumab in relapsed or refractory gray-zone lymphoma, primary central nervous system lymphoma, and other extranodal diffuse large B-cell lymphomas

2

Recruiting

–

NCT03255018

–

Pembrolizumab

Untreated B-NHLs

Pembrolizumab in untreated B-cell non-Hodgkin’s lymphoproliferative diseases

2

Recruiting

–

NCT03498612

–

Pembrolizumab

Relapsed or refractory stage IB-IVB MF/SS

A phase 2 study of pembrolizumab for the treatment of relapsed or refractory mycosis fungoides/Sézary syndrome

2

Completed

37.5%/8.3%

NCT02243579

–

Pembrolizumab

Stage IB-IV MF

Pembrolizumab in treating patients with stage IB-IV mycosis fungoides

2

Recruiting

–

NCT03695471

–

Pembrolizumab

Early stage NKTCL, nasal type

Study of pembrolizumab in patients with early stage NK/T-Cell lymphoma, nasal type

2

Recruiting

–

NCT03728972

–

Pembrolizumab, umbralisib

Relapsed or refractory B-NHLs/CLL

Combination of pembrolizumab with umbralisib in patients with relapsed or refractory CLL and B-NHLs

1

Recruiting

–

NCT03283137

–

Pembrolizumab, lenalidomide

Relapsed NHLs/HL

Efficacy and safety study of combination of pembrolizumab and lenalidomide, in patients with relapsed non-Hodgkin’s and Hodgkin’s lymphoma

1/2

Active, not recruiting

–

NCT02875067

–

Pembrolizumab, mogamulizumab

Relapsed or refractory NHLs/HL

Pembrolizumab and mogamulizumab in treating patients with relapsed or refractory lymphomas

1/2

Recruiting

–

NCT03309878

–

Pembrolizumab, rituximab

Relapsed or refractory DLBCL/FL

Pembrolizumab and rituximab in treating patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma

2

Recruiting

–

NCT03401853

–

Pralatrexate

Relapsed or refractory mature T- and NK-cell NHLs/MF

Pembrolizumab and pralatrexate in treating participants with relapsed or refractory peripheral T-cell lymphoma

1/2

Recruiting

–

NCT03598998

–

Pembrolizumab, tisagenlecleucel

Relapsed or refractory DLBCL

Study of pembrolizumab in combination with tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma patients

1

Recruiting

–

NCT03630159

–

Pembrolizumab, EBRT

Relapsed or refractory NHLs

Pembrolizumab and external beam radiation therapy in treating participants with relapsed or refractory non-Hodgkin lymphomas

2

Recruiting

–

NCT03210662

–

Pembrolizumab, radiotherapy

Relapsed or refractory MF/SS

A trial assessing the effect of pembrolizumab combined with radiotherapy in patients with relapsed or refractory, specified stages of cutaneous T-cell lymphoma mycosis fungoides/Sézary syndrome (PORT)

2

Recruiting

–

NCT03385226

–